Revenue forecast of AbbVie's Humira 2018-2024

In 2018, AbbVie's top product Humira generated nearly 20 billion U.S. dollars of revenue. Due to patent loss and biosimilars competition, it is expected that the revenue will decrease to some 13 billon dollars until 2024. Due to Abbot Laboratories was a U.S.-based global pharmaceutical and healthcare products company, headquartered in Chicago, Illinois. In January 2013, Abbott was separated into two companies: Abbott and AbbVie. Abbott is now specialized on medical products, while AbbVie is responsible for research-based pharmaceuticals.

Forecasted revenue for AbbVie's top product Humira from 2018 to 2024

Revenue in billion U.S. dollars
--
--
--
--
--
--
--
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $59 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

January 2019

Region

Worldwide

Survey time period

as of January 2019

Supplementary notes

* Actual figure; all other values are forecasted.

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.

Statistics on "Pharmaceutical brands: Humira (AbbVie)"

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.